Table 3.
Overall results and subgroup/sensitivity analyses.
| Variables | Heterogeneity | Meta-analyses | ||||
|---|---|---|---|---|---|---|
| I-square | p value | Model | OR (95% CI) | p value | ||
| Overall | 88.1% | <0.001 | Random | 1.340 (0.677–2.653) | 0.400 | |
| Stage | I - III | 93.6% | <0.001 | Random | 1.535 (0.433–5.441) | 0.507 |
| II - III | 0.0% | 0.557 | Fixed | 1.068 (0.754–1.512) | 0.711 | |
| Subtype | HER2- | 0.0% | 0.698 | Fixed | 0.935 (0.716–1.221) | 0.622 |
| TNBC | 0.0% | 0.800 | Fixed | 1.028 (0.779–1.356) | 0.846 | |
| Study type* | PCS | 95.7% | <0.001 | Random | 2.241 (0.410–12.259) | 0.352 |
| RCT | 0.0% | 0.487 | Fixed | 0.930 (0.674–1.283) | 0.659 | |
| Quality Score* | Low | 95.7% | <0.001 | Random | 2.241 (0.410–12.259) | 0.352 |
| High | 0.0% | 0.487 | Fixed | 0.930 (0.674–1.283) | 0.659 | |
| Study population& | Subgroup | 0.0% | 0.800 | Fixed | 1.028 (0.779–1.356) | 0.846 |
| Whole cohort | 96.1% | <0.001 | Random | 1.950 (0.212–17.913) | 0.555 | |
| BRCA status* | BRCA1 only | 95.7% | <0.001 | Random | 2.241 (0.410–12.259) | 0.352 |
| BRCA1 & 2 | 0.0% | 0.487 | Fixed | 0.930 (0.674–1.283) | 0.659 | |
| Experiment regimen& | Combination | 0.0% | 0.800 | Fixed | 1.028 (0.779–1.356) | 0.846 |
| Single | 96.1% | <0.001 | Random | 1.950 (0.212–17.913) | 0.555 | |
| Platinum& | Carboplatin | 0.0% | 0.800 | Fixed | 1.028 (0.779–1.356) | 0.846 |
| Cisplatin | 96.1% | <0.001 | Random | 1.950 (0.212–17.913) | 0.555 | |
CI, Confidence interval; OR, Odds ratio; PCS, Prospective cohort study; RCT, Randomized control trial; TNBC, Triple negative breast cancer.
*Collinearity existed among these three variables, so the subgroup analyses based on these three variables drew the same conclusion.
&Collinearity existed among these three variables, so the subgroup analyses based on these three variables drew the same conclusion.